1. Home
  2. TK vs GHRS Comparison

TK vs GHRS Comparison

Compare TK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teekay Corporation

TK

Teekay Corporation

HOLD

Current Price

$14.06

Market Cap

937.1M

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$21.48

Market Cap

947.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TK
GHRS
Founded
1973
2018
Country
Bermuda
Ireland
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
937.1M
947.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
TK
GHRS
Price
$14.06
$21.48
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
421.8K
252.6K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
15.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.12
$9.52
52 Week High
$14.22
$24.66

Technical Indicators

Market Signals
Indicator
TK
GHRS
Relative Strength Index (RSI) 64.89 62.50
Support Level $12.09 $12.41
Resistance Level N/A $24.66
Average True Range (ATR) 0.45 1.48
MACD 0.08 0.08
Stochastic Oscillator 86.88 68.22

Price Performance

Historical Comparison
TK
GHRS

About TK Teekay Corporation

Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: